PODXL

PODXL
Identifiers
AliasesPODXL, Gp200, PC, PCLP, PCLP-1, podocalyxin like
External IDsHomoloGene: 136790 GeneCards: PODXL
Gene location (Human)
Chr.Chromosome 7 (human)[1]
Band7q32.3Start131,500,262 bp[1]
End131,558,217 bp[1]
RNA expression pattern
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez

5420

n/a

Ensembl

ENSG00000128567

n/a

UniProt

O00592

n/a

RefSeq (mRNA)

NM_005397
NM_001018111

n/a

RefSeq (protein)

NP_001018121
NP_005388

n/a

Location (UCSC)Chr 7: 131.5 – 131.56 Mbn/a
PubMed search[2]n/a
Wikidata
View/Edit Human

Podocalyxin-like protein 1 is a protein that in humans is encoded by the PODXL gene.[3]

Function

This gene encodes a member of the CD34 sialomucin protein family.[4] The encoded protein was originally identified as an important component of glomerular podocytes. Inactivation of the encoding gene in mice leads to anuria, omphalocele and perinatal death.[5] Podocytes are highly differentiated epithelial cells with interdigitating foot processes covering the outer aspect of the glomerular basement membrane. Other biological activities of the encoded protein include: binding in a membrane protein complex with Na+/H+ exchanger regulatory factor to intracellular cytoskeletal elements, playing a role in hematopoetic cell differentiation, and being expressed in vascular endothelium cells and binding to L-selectin.[3]

Expression

The expression and localisation of PODXL in human cells, tissues and organs have been investigated by the Human Protein Atlas consortium[6]. According to antibody-based profiling, the protein is present in glomerular podocytes, endothelial cells, glandular cells in fallopian tube, uterus and seminal vesicle and according to RNA expression analysis, the PODXL transcripts are present in all analysed human tissues[7]. Based on confocal microscopy[8], the protein is mainly localised to the plasma membrane and microtubule organizing center and in addition localized to vesicles[9].

Interactions

PODXL has been shown to interact with Sodium-hydrogen exchange regulatory cofactor 2.[10][11][12]

Clinical significance

Podocalyxin is upregulated in a number of cancers and is frequently associated with poor prognosis[13][14]. Based on patient survival data[15], high level of PODXL transcripts in tumor cells is associated with poor prognosis in renal cancer.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000128567 - Ensembl, May 2017
  2. ↑ "Human PubMed Reference:".
  3. 1 2 "Entrez Gene: PODXL podocalyxin-like".
  4. ↑ Nielsen JS, McNagny KM (November 2008). "Novel functions of the CD34 family". Journal of Cell Science. 121 (Pt 22): 3683–92. doi:10.1242/jcs.037507. PMID 18987355.
  5. ↑ Doyonnas R, Kershaw DB, Duhme C, Merkens H, Chelliah S, Graf T, McNagny KM (July 2001). "Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin". The Journal of Experimental Medicine. 194 (1): 13–27. doi:10.1084/jem.194.1.13. PMC 2193439. PMID 11435469.
  6. ↑ Uhlen et al (2015) Science 347: 1260419. https://doi.org/doi:10.1126/science.1260419
  7. ↑ http://www.proteinatlas.org/ENSG00000128567-PODXL/tissue
  8. ↑ Thul et al (2017) Science 356 (6340): eaal3321. https://doi.org/doi:10.1126/science.aal3321
  9. ↑ http://www.proteinatlas.org/ENSG00000128567-PODXL/cell
  10. ↑ Meder D, Shevchenko A, Simons K, Füllekrug J (Jan 2005). "Gp135/podocalyxin and NHERF-2 participate in the formation of a preapical domain during polarization of MDCK cells". The Journal of Cell Biology. 168 (2): 303–13. doi:10.1083/jcb.200407072. PMC 2171597. PMID 15642748.
  11. ↑ Takeda T, McQuistan T, Orlando RA, Farquhar MG (Jul 2001). "Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton". The Journal of Clinical Investigation. 108 (2): 289–301. doi:10.1172/JCI12539. PMC 203027. PMID 11457882.
  12. ↑ Li Y, Li J, Straight SW, Kershaw DB (Jun 2002). "PDZ domain-mediated interaction of rabbit podocalyxin and Na(+)/H(+) exchange regulatory factor-2". American Journal of Physiology. Renal Physiology. 282 (6): F1129–39. doi:10.1152/ajprenal.00131.2001. PMID 11997330.
  13. ↑ Snyder KA, Hughes MR, Hedberg B, Brandon J, Hernaez DC, Bergqvist P, Cruz F, Po K, Graves ML, Turvey ME, Nielsen JS, Wilkins JA, McColl SR, Babcook JS, Roskelley CD, McNagny KM (March 2015). "Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy". Breast Cancer Research. 17 (1): 46. doi:10.1186/s13058-015-0562-7. PMC 4423095. PMID 25887862.
  14. ↑ McNagny KM, Hughes MR, Graves ML, DeBruin EJ, Snyder K, Cipollone J, Turvey M, Tan PC, McColl S, Roskelley CD (2012). "Podocalyxin in the Diagnosis and Treatment of Cancer". In Mohan R. Advances in Cancer Management. InTech. doi:10.5772/24274. ISBN 978-953-307-870-0.
  15. ↑ Uhlen et al (2017) Science 357 (6352): eaan2507. https://doi.org/doi:10.1126/science.aan2507

Further reading

  • Maruyama K, Sugano S (Jan 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298.
  • Kershaw DB, Beck SG, Wharram BL, Wiggins JE, Goyal M, Thomas PE, Wiggins RC (Jun 1997). "Molecular cloning and characterization of human podocalyxin-like protein. Orthologous relationship to rabbit PCLP1 and rat podocalyxin". The Journal of Biological Chemistry. 272 (25): 15708–14. doi:10.1074/jbc.272.25.15708. PMID 9188463.
  • Kershaw DB, Wiggins JE, Wharram BL, Wiggins RC (Oct 1997). "Assignment of the human podocalyxin-like protein (PODXL) gene to 7q32-q33". Genomics. 45 (1): 239–40. doi:10.1006/geno.1997.4934. PMID 9339384.
  • Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (Oct 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.
  • Sassetti C, Tangemann K, Singer MS, Kershaw DB, Rosen SD (Jun 1998). "Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: parallels to CD34". The Journal of Experimental Medicine. 187 (12): 1965–75. doi:10.1084/jem.187.12.1965. PMC 2212365. PMID 9625756.
  • Dias Neto E, Correa RG, Verjovski-Almeida S, Briones MR, Nagai MA, da Silva W, Zago MA, Bordin S, Costa FF, Goldman GH, Carvalho AF, Matsukuma A, Baia GS, Simpson DH, Brunstein A, de Oliveira PS, Bucher P, Jongeneel CV, O'Hare MJ, Soares F, Brentani RR, Reis LF, de Souza SJ, Simpson AJ (Mar 2000). "Shotgun sequencing of the human transcriptome with ORF expressed sequence tags". Proceedings of the National Academy of Sciences of the United States of America. 97 (7): 3491–6. doi:10.1073/pnas.97.7.3491. PMC 16267. PMID 10737800.
  • Takeda T, McQuistan T, Orlando RA, Farquhar MG (Jul 2001). "Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton". The Journal of Clinical Investigation. 108 (2): 289–301. doi:10.1172/JCI12539. PMC 203027. PMID 11457882.
  • Li Y, Li J, Straight SW, Kershaw DB (Jun 2002). "PDZ domain-mediated interaction of rabbit podocalyxin and Na(+)/H(+) exchange regulatory factor-2". American Journal of Physiology. Renal Physiology. 282 (6): F1129–39. doi:10.1152/ajprenal.00131.2001. PMID 11997330.
  • Schopperle WM, Kershaw DB, DeWolf WC (Jan 2003). "Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin". Biochemical and Biophysical Research Communications. 300 (2): 285–90. doi:10.1016/S0006-291X(02)02844-9. PMID 12504081.
  • Koop K, Eikmans M, Baelde HJ, Kawachi H, De Heer E, Paul LC, Bruijn JA (Aug 2003). "Expression of podocyte-associated molecules in acquired human kidney diseases". Journal of the American Society of Nephrology. 14 (8): 2063–71. doi:10.1097/01.ASN.0000078803.53165.C9. PMID 12874460.
  • Brandenberger R, Wei H, Zhang S, Lei S, Murage J, Fisk GJ, Li Y, Xu C, Fang R, Guegler K, Rao MS, Mandalam R, Lebkowski J, Stanton LW (Jun 2004). "Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation". Nature Biotechnology. 22 (6): 707–16. doi:10.1038/nbt971. PMID 15146197.
  • Economou CG, Kitsiou PV, Tzinia AK, Panagopoulou E, Marinos E, Kershaw DB, Kerjaschki D, Tsilibary EC (Jul 2004). "Enhanced podocalyxin expression alters the structure of podocyte basal surface". Journal of Cell Science. 117 (Pt 15): 3281–94. doi:10.1242/jcs.01163. PMID 15226400.
  • Somasiri A, Nielsen JS, Makretsov N, McCoy ML, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, McNagny KM, Roskelley CD (Aug 2004). "Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression". Cancer Research. 64 (15): 5068–73. doi:10.1158/0008-5472.CAN-04-0240. PMID 15289306.
  • Suzuki Y, Yamashita R, Shirota M, Sakakibara Y, Chiba J, Mizushima-Sugano J, Nakai K, Sugano S (Sep 2004). "Sequence comparison of human and mouse genes reveals a homologous block structure in the promoter regions". Genome Research. 14 (9): 1711–8. doi:10.1101/gr.2435604. PMC 515316. PMID 15342556.
  • Meder D, Shevchenko A, Simons K, Füllekrug J (Jan 2005). "Gp135/podocalyxin and NHERF-2 participate in the formation of a preapical domain during polarization of MDCK cells". The Journal of Cell Biology. 168 (2): 303–13. doi:10.1083/jcb.200407072. PMC 2171597. PMID 15642748.
  • Casey G, Neville PJ, Liu X, Plummer SJ, Cicek MS, Krumroy LM, Curran AP, McGreevy MR, Catalona WJ, Klein EA, Witte JS (Mar 2006). "Podocalyxin variants and risk of prostate cancer and tumor aggressiveness". Human Molecular Genetics. 15 (5): 735–41. doi:10.1093/hmg/ddi487. PMID 16434482.
  • Butta N, Larrucea S, Alonso S, Rodriguez RB, Arias-Salgado EG, Ayuso MS, González-Manchón C, Parrilla R (2006). "Role of transcription factor Sp1 and CpG methylation on the regulation of the human podocalyxin gene promoter". BMC Molecular Biology. 7: 17. doi:10.1186/1471-2199-7-17. PMC 1481587. PMID 16684343.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.